Janus Kinase Inhibitors: all 1,428 studies that test it

Page 7 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative ColitisCompletedNCT02914522Phase 3Results posted
• Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell TransplantationCompletedNCT02913261Phase 3Results posted
• A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune SuppressionCompletedNCT02891603Phase 1/2Results posted
• Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateCompletedNCT02889796Phase 3Results posted
• Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX TherapyCompletedNCT02886728Phase 3Results posted
• Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerCompletedNCT02876302Phase 2Results posted
• Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) TreatmentCompletedNCT02873936Phase 3Results posted
• Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid ArthritisCompletedNCT02831855Phase 4Results posted
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)CompletedNCT02819635Phase 2/3Results posted
• Topical Tofacitinib for the Treatment of Alopecia Areata and Its VariantsCompletedNCT02812342Phase 2Results posted
• Topical Ruxolitinib for the Treatment of VitiligoCompletedNCT02809976Phase 2Results posted
• Long-Term Side Effects of Ruxolitinib in Treating Patients With MyelofibrosisCompletedNCT02784496Phase 2Results posted
• A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's DiseaseCompletedNCT02782663Phase 2Results posted
• Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic DermatitisCompletedNCT02780167Phase 2Results posted
• A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02760485Phase 1/2Results posted
• Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02759731Phase 1/2Results posted
• A Study of Baricitinib (LY3009104) in Healthy Chinese ParticipantsCompletedNCT02758613Phase 1Results posted
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDsCompletedNCT02720523Phase 2/3Results posted
• A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisTerminatedNCT02718300Phase 2Results posted
• Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02713386Phase 1/2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)CompletedNCT02708095Phase 2Results posted
• A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateCompletedNCT02706873Phase 3Results posted
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDsCompletedNCT02706847Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs AloneCompletedNCT02675426Phase 3Results posted
• Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.TerminatedNCT02598297Phase 3Results posted
• Efficacy Study Of Tofacitinib In Pediatric JIA PopulationCompletedNCT02592434Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT02576938Phase 2Results posted
• LEO 124249 Ointment in the Treatment of Alopecia AreataCompletedNCT02561585Phase 2Results posted
• A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)TerminatedNCT02553330Phase 2Results posted
• Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)CompletedNCT02515630Phase 2Results posted
• Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected AdultsCompletedNCT02475655Phase 2Results posted
• Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT02469415Phase 2Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseTerminatedNCT02436135Phase 1Results posted
• Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaTerminatedNCT02420717Phase 2Results posted
• Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)TerminatedNCT02410551Phase 2Results posted
• A Pilot Study of Ruxolitinib in Secondary Hemophagocytic SyndromeCompletedNCT02400463Phase 2Results posted
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF TherapyCompletedNCT02365649Phase 2Results posted
• A Study to Measure Baricitinib (LY3009104) Absorption in Healthy ParticipantsCompletedNCT02340104Phase 1Results posted
• Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis PatientsCompletedNCT02321930Phase 4Results posted
• Tofacitinib for the Treatment of Alopecia Areata and Its VariantsCompletedNCT02312882Not applicableResults posted
• A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect InvestigationCompletedNCT02310750Phase 1Results posted
• A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDsCompletedNCT02308163Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) TreatmentCompletedNCT02305849Phase 3Results posted
• Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And UniversalisCompletedNCT02299297Phase 2Results posted
• Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.CompletedNCT02292446Phase 3Results posted
• A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid ArthritisCompletedNCT02281552Phase 3Results posted
• Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal CancerTerminatedNCT02277093Phase 2Results posted
• Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)CompletedNCT02267278Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)CompletedNCT02265705Phase 3Results posted
• A Study of Baricitinib in Healthy Japanese ParticipantsCompletedNCT02263911Phase 1Results posted
• Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid LeukemiaCompletedNCT02257138Phase 1/2Results posted
• JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT02251821Phase 2Results posted
• Study to Evaluate PF-04965842 in Patients With Moderate to Severe PsoriasisTerminatedNCT02201524Phase 2Results posted
• An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With MethotrexateCompletedNCT02187055Phase 4Results posted
• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesCompletedNCT02158858Phase 1/2Results posted
• Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibCompletedNCT02155465Phase 1/2Results posted
• A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background MethotrexateCompletedNCT02147587Phase 2Results posted
• Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaCompletedNCT02124746Phase 2Results posted
• A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerTerminatedNCT02120417Phase 2Results posted
• Study of Ruxolitinib in Colorectal Cancer PatientsTerminatedNCT02119676Phase 2Results posted
• A Study of Ruxolitinib in Pancreatic Cancer PatientsTerminatedNCT02119663Phase 3Results posted
• Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerTerminatedNCT02119650Phase 2Results posted
• Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)TerminatedNCT02117479Phase 3Results posted
• Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFCompletedNCT02101268Phase 3Results posted
• Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT02101021Phase 3Results posted
• Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid ArthritisCompletedNCT02092467Phase 4Results posted
• Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid LeukemiaCompletedNCT02092324Phase 2Results posted
• A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)TerminatedNCT02091752Phase 2Results posted
• A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) MyelofibrosisCompletedNCT02087059Phase 3Results posted
• Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast CancerCompletedNCT02066532Phase 1/2Results posted
• A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX AloneCompletedNCT02066389Phase 2Results posted
• Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsCompletedNCT02065700Phase 2Results posted
• Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and ThrombocytopeniaTerminatedNCT02055781Phase 3Results posted
• Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.CompletedNCT02049450Phase 2Results posted
• An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid ArthritisCompletedNCT02049138Phase 2Results posted
• Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory BrcaCompletedNCT02041429Phase 1/2Results posted
• Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.CompletedNCT02038036Phase 3Results posted
• A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)CompletedNCT02018861Phase 1/2Results posted
• Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)CompletedNCT02001181Phase 2Results posted
• Open-Label Extension Study Of Tofacitinib In Psoriatic ArthritisCompletedNCT01976364Phase 3Results posted
• Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisCompletedNCT01969838Phase 3Results posted
• A Study of Baricitinib and Ciclosporin in Healthy ParticipantsCompletedNCT01968057Phase 1Results posted
• A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic TherapyCompletedNCT01960855Phase 2Results posted
• A Study of Baricitinib and Simvastatin in Healthy ParticipantsCompletedNCT01960140Phase 1Results posted
• Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia AreataCompletedNCT01950780Phase 2Results posted
• A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy ParticipantsCompletedNCT01924299Phase 1Results posted
• A Study of Baricitinib and Rifampicin in Healthy ParticipantsCompletedNCT01910311Phase 1Results posted
• A Study of Baricitinib and Birth Control Pills in Healthy FemalesCompletedNCT01896726Phase 1Results posted
• Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)CompletedNCT01894516Phase 2Results posted
• Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)CompletedNCT01888874Phase 2Results posted
• An Extension Study in Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT01885078Phase 3Results posted
• Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF InhibitorsCompletedNCT01882439Phase 3Results posted
• Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator StudyCompletedNCT01877668Phase 3Results posted
• A Pharmacokinetic Study of Baricitinib in Participants With Liver DiseaseCompletedNCT01870388Phase 1Results posted
• A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy ParticipantsCompletedNCT01859078Phase 1Results posted
• Tofacitinib Ointment For Chronic Plaque PsoriasisCompletedNCT01831466Phase 2Results posted
• A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque PsoriasisCompletedNCT01815424Phase 3Results posted
• Ruxolitinib Prior to Transplant in Patients With MyelofibrosisTerminatedNCT01790295Phase 2Results posted
• A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFCompletedNCT01787552Phase 1/2Results posted
• Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing SpondylitisCompletedNCT01786668Phase 2Results posted

← Janus Kinase Inhibitors overview